Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02543229
Other study ID # OPT-302-1001
Secondary ID
Status Completed
Phase Phase 1
First received August 25, 2015
Last updated November 2, 2017
Start date July 2015
Est. completion date September 2017

Study information

Verified date November 2017
Source Opthea Limited
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this first-in-human study is to evaluate the safety, pharmacokinetics (PK) and pharmacodynamics of OPT-302 administered as monthly intravitreal injections for 3 months with and without Lucentis™ in patients with wet age related macular degeneration (AMD). This study will be conducted in two parts: Part 1 will comprise an open label, sequential dose escalation and Part 2 a randomized dose expansion.

OPT-302 is a soluble form of VEGFR-3 comprising the extracellular domains 1-3 of human vascular endothelial growth factor receptor (VEGFR)-3 and the Fc fragment of human IgG1. It functions by binding and neutralizing the activity of vascular endothelial growth factor (VEGF)-C and VEGF-D on endogenous VEGFR-2 and VEGFR-3.

VEGF-C and VEGF-D promote blood vessel development (angiogenesis) by binding and activating VEGFR-2 and VEGFR-3. VEGF-C is also a potent inducer of vascular permeability or leakage. Angiogenesis and vascular leakage are key hallmarks of wet AMD. Approved therapies for wet AMD include Eylea™ and Lucentis™ which block the activity of VEGF-A, but not VEGF-C or VEGF-D which are alternate members of the same family of molecules.

VEGF-C and VEGF-D can stimulate blood vessel growth and leakage through the same pathway as VEGF-A (via VEGFR-2), as well as through pathways that are independent of VEGF-A (via VEGFR-3). Published studies have also indicated that VEGF-C and VEGF-D play an important role in mediating resistance to therapies that block VEGF-A such as Lucentis™ and Eylea™.

Combination therapy with OPT-302 an anti-VEGF-A agent provides a more complete blockade of the VEGF family. This strategy targets functional redundancy in the VEGF pathway and mechanisms of 'resistance' or sub-response to VEGF-A inhibition.


Recruitment information / eligibility

Status Completed
Enrollment 51
Est. completion date September 2017
Est. primary completion date February 7, 2017
Accepts healthy volunteers No
Gender All
Age group 50 Years and older
Eligibility Inclusion Criteria:

- Able and willing to provide written informed consent

- Age = 50 years of either gender

- Active CNV lesions secondary to AMD (i.e., subretinal or intraretinal fluid on SD-OCT and / or leakage on fluorescein angiography)

- Either no previous treatment in the study eye with IVT anti-VEGF-A therapy (treatment naïve) or prior IVT anti-VEGF-A therapy (previously treated) with sub-optimal response to treatment and the need for additional treatment

- Best corrected visual acuity in the study eye, using ETDRS testing, of 20/320 or better (Snellen equivalent) in Part 1 (dose escalation) and between 20/40 and 20/320 (Snellen equivalent), inclusive, in Part 2 (dose expansion).

- Women of child bearing potential and male subjects with female partners of child bearing potential must be practicing effective contraception during the trial and for at least 3 months following the last dose of study medication

Exclusion Criteria:

- Previous or concurrent use of systemic anti-VEGF-A agents

- Most recent IVT injection of bevacizumab or ranibizumab <28 days prior to screening or aflibercept <42 days prior to screening

- Previous treatment with photodynamic therapy, thermal laser or external beam radiation in the study eye

- Concurrent treatment in either eye for any ocular condition with an investigational drug or device that has not received regulatory approval

- Anatomic damage to the center of the fovea including fibrosis and scarring making up >50% of total lesion area including the CNV in the study eye

- Geographic atrophy involving the center of the fovea in the study eye

- History or presence of a retinal pigment epithelial tear

- Presence of polypoidal choroidal vasculopathy (if in the opinion of the investigator, anti-VEGF treatment would not be of benefit) or retinal angiomatous proliferation

- Active or recent (within 4 weeks) intraocular inflammation (grade trace or above) in the study eye

- History of rhegmatogenous retinal detachment or macular hole in the study eye

- History of vitrectomy

- Active infectious conjunctivitis, keratitis, scleritis, or endophthalmitis in either eye

- History of vitreous hemorrhage within 4 weeks prior to screening in the study eye

- History of major ocular surgery within prior 6 months or anticipated within next 3 months following dosing on day 1

- Uncontrolled glaucoma in the study eye (defined as intraocular pressure of >25 mmHg despite treatment with maximal medical therapy)

- Uncontrolled hypertension =180 mmHg systolic or =110 mmHg diastolic at baseline

- Uncontrolled diabetes mellitus (Disease must be controlled with hemoglobin A1c (HgbA1c) < 9.0%)

- Clinical evidence of diabetic retinopathies, diabetic macular edema or any other vascular disease affecting the retina, other than AMD, in either eye that, in the opinion of the investigator, would be likely to limit improvement in the macular anatomy and/or function

- Pregnancy or lactation

Study Design


Intervention

Drug:
OPT-302
OPT-302 will be administered by intravitreal injection once every month for 3 months
Lucentis™
Lucentis™ (0.5 mg) will be administered by intravitreal injection once every month for 3 months

Locations

Country Name City State
United States Opthea Investigative Site Abilene Texas
United States Opthea Investigative Site Beverly Hills California
United States Opthea Investigative Site Bloomfield New Jersey
United States Opthea Investigative Site Charlotte North Carolina
United States Opthea Investigative Site Cleveland Ohio
United States Opthea Investigative Site Fort Myers Florida
United States Opthea Investigative Site Pensacola Florida
United States Opthea Investigative Site Phoenix Arizona
United States Opthea Investigative Site Sacramento California
United States Opthea Investigative Site Santa Maria California
United States Opthea Investigative Site West Columbia South Carolina
United States Opthea Investigative Site Wichita Kansas
United States Opthea Investigative Site Willow Park Texas
United States Opthea Investigative Site Winter Haven Florida

Sponsors (1)

Lead Sponsor Collaborator
Opthea Limited

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Exploratory: Changes in the systemic blood levels of angiogenesis-related biomarkers Change in systemic blood levels of angiogenesis-related biomarkers including, but not limited to: Vascular Endothelial Growth Factor A (VEGF-A), VEGF-C, VEGF-D, soluble VEGFR-2 and soluble VEGFR-3. 3 months
Primary Safety (Adverse Events) Subject incidences of ophthalmic and systemic Adverse Events during study and follow-up period Up to 1 month after the last dose
Secondary Mean change in Best Corrected Visual Acuity (BCVA) from baseline Mean change in Early Treatment Diabetic Retinopathy Study (ETDRS) BCVA from baseline 6 months
Secondary Mean change in central retinal thickness from baseline Changes in intra- or sub-retinal fluid measured as mean change in central retinal thickness or macula volume by Spectral Domain Optical Coherence Tomography (SD-OCT) 6 months
Secondary Mean change in Choroidal Neovascularization (CNV) lesion area from baseline Change in CNV size according to fluorescein angiogram 6 months
Secondary Mean number of retreatment injections of anti-VEGF-A therapy during long term follow-up (week 12 to 24) 3 months
Secondary Need for 'rescue therapy' with ranibizumab in subjects receiving OPT-302 monotherapy 3 months
Secondary Assess the Pharmacokinetic profile of OPT-302 alone and in combination with ranibizumab following intravitreal administration Mean systemic OPT-302 Concentration-Time profile Up to 28 days post-dose
Secondary Anti-OPT-302 antibody formation Incidence of anti-OPT-302 antibody formation Pre-dose and up to 3 months post-dose
See also
  Status Clinical Trial Phase
Recruiting NCT06262737 - Single-center Study Measuring OSDI Dry Eye Score in Patients Undergoing an Anti-VEGF Induction Protocol
Completed NCT02540954 - Efficacy and Safety of Two Different Aflibercept Regimens in Subjects With Neovascular Age-related Macular Degeneration (nAMD) Phase 3
Completed NCT00385333 - Metabolic Mapping to Measure Retinal Metabolism Phase 2
Completed NCT02510794 - Study of the Efficacy and Safety of the Ranibizumab Port Delivery System for Sustained Delivery of Ranibizumab in Patients With Subfoveal Neovascular Age-Related Macular Degeneration Phase 2
Completed NCT02181504 - A Study of Abicipar Pegol in Japanese Patients With Neovascular Age-related Macular Degeneration Phase 2
Completed NCT02390245 - Philadelphia Telemedicine Glaucoma Detection and Follow-Up Study N/A
Terminated NCT02228304 - Study of the Intravitreal Implantation of NT-503-3 Encapsulated Cell Technology (ECT) for the Treatment of Recurrent Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD) Phase 1/Phase 2
Recruiting NCT01521065 - An Open-label Study to Evaluate the Clinical and Economic Benefits of I-Ray in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration Phase 2
Completed NCT01204541 - A Single-Center Pilot Study to Assess Macular Function N/A
Completed NCT00769392 - Pilot Study: A Randomized Trial Of Anesthetic Agents For Intravitreal Injection N/A
Completed NCT00533520 - Evaluation of Dosing Interval of Higher Doses of Ranibizumab Phase 4
Completed NCT00536016 - A Phase 1 Safety Study of Single and Repeated Doses of JSM6427 (Intravitreal Injection) to Treat AMD Phase 1
Withdrawn NCT00538538 - Subretinal Lucentis for Hemorrhagic Age-related Macular Degeneration (AMD) Phase 1
Terminated NCT00403442 - Bevacizumab in Combination With Verteporfin Reduced and Standard Fluence in the Treatment of Hemorrhaged Lesions in Neovascular AMD Phase 1
Recruiting NCT00157976 - Double-Masked Study of Photrex (Rostaporfin) Photodynamic Therapy in the Treatment of Age-Related Macular Degeneration Phase 3
Completed NCT00242580 - A Safety and Efficacy Study Comparing the Combination Treatments of Verteporfin Therapy Plus One of Two Different Doses of Intravitreal Triamcinolone Acetonide and the Verteporfin Therapy Plus Intravitreal Pegaptanib Phase 3
Completed NCT00239928 - Clinical Study Of Pegaptanib Sodium (EYE001) For Wet-Type Age-Related Macular Degeneration Phase 2
Completed NCT00211458 - Treatment of Age-Related Macular Degeneration With Anecortave Acetate Phase 2
Completed NCT00095433 - Extension Study of rhuFab V2 in Subjects With Neovascular Age-Related Macular Degeneration (AMD) Phase 3
Completed NCT00006202 - Lutein for Age-Related Macular Degeneration Phase 2